Laryngeal cartilage cancer

Summary

Laryngeal cartilage cancer (MONDO:0001691) is a cancer. A subtype of musculoskeletal system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	laryngeal cartilage cancer
Mondo ID	MONDO:0001691
DOID	DOID:13348
ICD-10-CM	C32.3
ICD-11	697702574
SNOMED CT	363431006
UMLS	C0153486
MedGen	509306
GARD	0022988
Anatomy (UBERON)	UBERON:0001739
Is cancer (heuristic)	yes

Also known as: cancer of laryngeal cartilage · laryngeal cartilage cancer · malignant laryngeal cartilage neoplasm · malignant neoplasm of laryngeal cartilage · malignant neoplasm of laryngeal cartilages · malignant tumour of laryngeal cartilage

Disease family

This is a subtype of musculoskeletal system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › laryngeal cartilage cancer

Related subtypes (10): cartilage cancer, broad ligament malignant neoplasm, round ligament malignant neoplasm, bone cancer, synovium cancer, uterine ligament cancer, tonsillar pillar cancer, gingival cancer, muscle cancer, ameloblastic carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.